Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maen Hussein

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
The Lancet. Oncology|May 16, 2022
Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 studyByoung Chul Cho, Delvys Rodriguez Abreu, Maen Hussein, et al.
Clinical Lung Cancer|April 7, 2024
A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON StudyEdward B Garon, Byoung Chul Cho, Alexander Luft, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 19, 2025
Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung CancerMelissa L Johnson, Egbert F Smit, Enriqueta Felip, et al.
JCO Precision Oncology|July 9, 2025
LODESTAR: A Single-Arm Phase II Study of Rucaparib in Solid Tumors With Pathogenic Germline or Somatic Variants in Homologous Recombination Repair GenesSriram Anbil, Nicholas J Seewald, E Gabriela Chiorean, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2020
Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153David M Waterhouse, Edward B Garon, Jason Chandler, et al.
Future Oncology (London, England)|March 30, 2026
A plain language summary of the updated results from the PHAROS study: the combination of encorafenib plus binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancerMelissa L Johnson, Egbert F Smit, Enriqueta Felip, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 7, 2024
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON TrialSolange Peters, Byoung Chul Cho, Alexander V Luft, et al.
Future Oncology (London, England)|February 15, 2024
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancerGregory J Riely, Egbert F Smit, Myung-Ju Ahn, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 19, 2016
PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung CancerHui Yu, Cory Batenchuk, Andrzej Badzio, et al.
The Oncologist|March 13, 2020
The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)Johanna C Bendell, Tamara Sauri, Antonio Cubillo Gracián, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
The Lancet. Oncology|May 16, 2022
Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 studyByoung Chul Cho, Delvys Rodriguez Abreu, Maen Hussein, et al.
Clinical Lung Cancer|April 7, 2024
A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON StudyEdward B Garon, Byoung Chul Cho, Alexander Luft, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 19, 2025
Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung CancerMelissa L Johnson, Egbert F Smit, Enriqueta Felip, et al.
JCO Precision Oncology|July 9, 2025
LODESTAR: A Single-Arm Phase II Study of Rucaparib in Solid Tumors With Pathogenic Germline or Somatic Variants in Homologous Recombination Repair GenesSriram Anbil, Nicholas J Seewald, E Gabriela Chiorean, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2020
Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153David M Waterhouse, Edward B Garon, Jason Chandler, et al.
Future Oncology (London, England)|March 30, 2026
A plain language summary of the updated results from the PHAROS study: the combination of encorafenib plus binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancerMelissa L Johnson, Egbert F Smit, Enriqueta Felip, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 7, 2024
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON TrialSolange Peters, Byoung Chul Cho, Alexander V Luft, et al.
Future Oncology (London, England)|February 15, 2024
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancerGregory J Riely, Egbert F Smit, Myung-Ju Ahn, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 19, 2016
PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung CancerHui Yu, Cory Batenchuk, Andrzej Badzio, et al.
The Oncologist|March 13, 2020
The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)Johanna C Bendell, Tamara Sauri, Antonio Cubillo Gracián, et al.
Pageof 3